Mydecine’s mission is to become a trusted source of safe and effective medication-based treatments to address the unmet needs for mental health and addiction disorders.

Mydecine – Medicine Evolved

Mydecine Innovations Group™ is a biotechnology company developing first- and second-generation novel therapeutics to treat mental health and addiction disorders. Using world-class technology and drug development infrastructure, we are advancing new treatment options in areas of significant unmet need. Our global team is progressing a robust research and development pipeline of psychedelic and non-psychedelic therapeutics, novel compounds and controlled drug delivery systems.

Publicly traded on: (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA)

Learn About Mydecine

Vertically Integrated

IP & Drug Development

We have multiple pending patents for novel first- and second-generation drugs with a focus on safety and efficacy, combined with an expert R&D team and cutting-edge research facilities in Canada and the U.S.

Discover the Potential

Clinical Trial Development

We’ve partnered with top global research organizations to investigate multiple drug candidates offering the potential for increased efficacy and additional improvements. Initial clinical trials will target nicotine dependence and PTSD.

View Clinical Trials


Technology is a key component of our business strategy, and we’re leveraging AI/ML technology to screen billions of molecules to identify promising new compounds. We also offer a virtual health platform to support patients throughout their mental health journey.

Discover Our Technology

Stock Information

Mydecine Innovations Group Inc.